Frederic P.
- Country
- France
- Department
- Hematology
Research Overview
- INCB 50465-801: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)
- Phase IB/II Study of Lenalidomide and Ibrutinib with R-MPV in Newly Diagnosed Primary Central Nervous System Lymphoma Patients Aged 18-65
Data & Insights
Has run more than one trial at 2 of 56 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating Primary Central Nervous System Lymphoma (PCNSL), with particular focus on developing targeted therapeutic approaches for newly diagnosed patients.
- CNS Lymphoma Management
- Novel Therapeutic Combinations
- Targeted Induction Treatments
Their research explores innovative treatment strategies for patients aged 18-65 with PCNSL.
Advanced Malignancies
The investigator focuses on evaluating novel therapeutic agents for advanced malignancies and exploring combination treatment approaches.
- Targeted Therapy Development
- Monotherapy Applications
- Combination Treatment Strategies
Their work encompasses the investigation of multiple therapeutic agents in various combinations for treating advanced cancers.
Immunological Disorders
The investigator studies treatments for inflammatory and autoimmune diseases (IAI), evaluating both single-agent and combination therapeutic approaches.
- Autoimmune Disease Management
- Novel Treatment Evaluation
- Long-term Treatment Safety
Their research includes continuous monitoring of treatment safety and efficacy in IAI conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.